Status:
NOT_YET_RECRUITING
Biomarkers in Systemic Histiocytosis
Lead Sponsor:
Assistance Publique - Hôpitaux de Paris
Conditions:
Systemic Histiocytosis (Disorder)
Eligibility:
All Genders
18+ years
Brief Summary
Systemic histiocytoses in adults (Langerhans cell histiocytosis, Erdheim-Chester disease, and Rosai-Dorfman disease) are rare inflammatory disorders in which recent discoveries have identified a clona...
Detailed Description
Systemic histiocytoses are rare diseases with a clinical spectrum ranging from mild forms to severe, life-threatening multi-organ involvement. Numerous recent studies have identified somatic mutations...
Eligibility Criteria
Inclusion
- Age ≥ 18 years
- Patient followed for systemic histiocytosis in Internal Medicine Department 2 at Pitié-Salpêtrière Hospital
- Non-opposition to participation in the study
Exclusion
- Pregnant or breastfeeding women
- Patients without French social security or covered by State Medical Aid (AME)
- Patients deprived of liberty by judicial or administrative decision, or under legal protection
Key Trial Info
Start Date :
October 1 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
October 1 2040
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT07157683
Start Date
October 1 2025
End Date
October 1 2040
Last Update
September 5 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Internal Medicine Department 2 at Pitié-Salpêtrière Hospital
Paris, France, 75013